Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Donate
Greater New Jersey
Change Location

Alzheimer’s Association Statement on Lecanemab Phase 3 Topline Data Release

Alzheimer’s Association Statement on Lecanemab Phase 3 Topline Data Release
Share or Print this page
Share or Print this page
September 27, 2022
Email:
Share or Print this page
CHICAGO, SEPT. 27, 2022 — On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.
 
These are the most encouraging results in clinical trials treating the underlying causes of Alzheimer’s to date. 
 
For people in the earliest stages of Alzheimer’s, this treatment has the potential to change the course of the disease in a clinically meaningful way. These results indicate lecanemab may give people more time at or near their full abilities to participate in daily life, remain independent and make future health care decisions. Treatments that deliver these benefits to those with mild cognitive impairment (MCI) due to Alzheimer’s disease and early Alzheimer’s dementia are just as valuable as treatments that extend the lives of those with other terminal diseases.
 
We look forward to learning more about data from CLARITY AD at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in November, including data on participant safety and representation. If those data are consistent with what we saw today regarding efficacy and safety, we strongly support FDA approval and full coverage.
 
The Centers for Medicare and Medicaid Services (CMS) recently implemented a National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease. As it stands, this NCD would severely limit Medicare coverage for lecanemab if it is approved for use by the Food and Drug Administration (FDA). CMS has pledged to move quickly to modify the NCD if warranted by new evidence. If full CLARITY AD results are in line with today’s topline announcement and the FDA approves this treatment, Medicare beneficiaries living with Alzheimer’s, a terminal, progressive disease, deserve the same immediate, full coverage under Medicare afforded to those with other terminal diseases.
 
Even with the success announced today, we must redouble efforts to discover new targets and test new and more effective treatments for Alzheimer’s and all other dementia. The Alzheimer’s Association has long been committed to advancing all potential treatment avenues and exploring methods for combining diverse approaches into combination therapies. We also must continue to advocate to ensure access to any approved treatments, as well as quality care and support for all people.

Alzheimer's Association

The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia.™ For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.

Keep Up With Alzheimer’s News and Events

The first survivor of Alzheimer's is out there, but we won't get there without you.

Donate Now

Learn how Alzheimer’s disease affects the brain.

Take the Brain Tour

Don't just hope for a cure. Help us find one. Volunteer for a
clinical trial.

Learn More

We use cookies to improve your experience on this website. Learn about options for managing your personal data in our Privacy Policy.